Status: Recruiting
rBCG-N-RSV Vaccine in Adults Aged 60 Years and Older
This Phase 2 clinical study will evaluate the safety of the rBCG-N-RSV vaccine compared to conventional BCG in adults older than 60 years. It will also compare the cellular anti-mycobacterial immune response of both vaccines in adults older than 60 years and characterize the cellular immune response against RSV nucleoprotein (N) generated by the rBCG-N-RSV vaccine in adults older than 60 years as compared to the response induced by the conventional BCG.
Participants needed: 200
Trial details
Phase: Phase 2Age: 60+Biological sex: AllType: InterventionalSponsor: Biothervax SpAUpdated: Sep 15, 2026Locations: 1
Eligibility criteria
Has completed the written informed consent process. [+2]
Willingness to comply with study procedures. [+38]